Open AccessCisplatin, Fluorouracil in Bolus Injection, and Leucovorin in First-Line Therapy for Advanced Gastric Cancer as an Alternative to Protocols With Infusional Fluorouracil
Author(s) -
Rafael Corrêa Coelho,
Pedro Duarte Abreu,
Mariana Ribeiro Monteiro,
Ana Paula Stramosk,
Alvaro Ingles Garces,
Andréia Cristina de Melo,
Marcia S Graudenz,
Carlos José Coelho de Andrade
Publication year - 2019
Publication title -
journal of global oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.002
H-Index - 17
ISSN - 2378-9506
DOI - 10.1200/jgo.18.00176
Subject(s) - medicine , fluorouracil , cisplatin , bolus (digestion) , oncology , chemotherapy , cancer
Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer death worldwide. Platinum agents and fluoropyrimidines are the main compounds used in the first-line setting for advanced GC. Given the activity of fluorouracil (FU) bolus, the PFL protocol, a chemotherapy regimen combining cisplatin, FU bolus, and leucovorin, was incorporated at the Brazilian National Cancer Institute, because this schedule does not require hospitalization or infusion pumps. This study aims to evaluate the outcomes of PFL in the first-line setting for patients with advanced GC.